ホスピス トクシマ ニオケル マッキ ガン カンジャ ノ ボウシュヨウセイ シンケイ ショウコウグン ノ ハッショウ ヒンド ト ソノ リンショウテキ イギ
Neurological syndrome of advanced cancer patients in Hospice Tokushima
Arase, Tomoko Kondo Hospital
Kondo, Akira Kondo Hospital
Tanida, Noriko Kondo Hospital
Tominaga, Emiko Kondo Hospital
Doi, Daisuke Kondo Hospital
Kato, Shuji Kondo Hospital
Kawai, Naoomi Kondo Hospital
Aihara, Kenichi Department of Medicine and Bioregulatory Sciences, Institute of Health Biosciences, The University of Tokushima Graduate School Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Ookura, Masao Tokushima Bunri University
Sakurai, Etu Sumitomo Clinic
Tanaka, Keiko Department of Neurology, Brain Research Institute, Niigata University
paraneoplastic neurological syndrome
advanced cancer patients
hospice palliative care
Neurological complications in advanced cancer occur frequently and therefore an adequate neurological assessment must always be part of patient evaluation in hospice palliative care. Paraneoplastic neurological syndromes are rare, probably affecting less than 1 per cent of patients with cancer, even if the most commonly associated neoplasms, such as small-cell lung cancer and ovarian cancer are considered. Neurological complications were studied in 127 inpatients with advanced cancers.
Neurological complications were seen in up to 40 per cent of the patients. The most frequent symptom was derilium, followed in order to lethargy, paraplegia, depression, dementia, hemiplegia, restlessness, aphasia, stupor, facial palsy, recurrent laryngeal nerve palsy, convulsion, and myastenia. Those symptoms were seen in patients in hepatic encephalitis（12）, metastatic brain tumor（9）, metastatic spinal cord injury（8）, depression（4）, paraneoplastic syndrome（4）, hypercalcemia（2）, senile dementia（2）, peripheral neuritis（2）, and cerebral infarction（2）. Of the four patients with paraneoplastic syndrome, one patient had both anti-Hu antibody and anti-VGCC antibody and two patients had anti-neuronal nuclear antibodies.
These results indicate that paraneoplastic neurological syndromes are associated more than 1 per cent of patients with advanced cancer.
LID201208271001.pdf 32 KB